Israel
Index Globenewswire
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
Jumat, 28 Maret 2025 - 21:48:52 Wib Globenewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Selasa, 18 Februari 2025 - 18:30:00 Wib Globenewswire
Value of AI, Cloud Solutions Reign in Cellebrite’s 2025 Annual Industry Trends Survey
Selasa, 11 Februari 2025 - 21:00:00 Wib Globenewswire
Cellebrite’s Generative AI Innovations Deliver a Powerful Assistant to Expedite Investigations
Kamis, 06 Februari 2025 - 21:33:15 Wib Globenewswire
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in Major Parts of Europe and in Israel
Senin, 13 Januari 2025 - 13:30:00 Wib Globenewswire
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Jumat, 10 Januari 2025 - 21:00:00 Wib Globenewswire
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Selasa, 24 Desember 2024 - 11:36:00 Wib Globenewswire
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Jumat, 06 Desember 2024 - 14:23:23 Wib Globenewswire
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Selasa, 26 November 2024 - 06:09:27 Wib Globenewswire
Teva to Present at the Jefferies London Healthcare Conference
Sabtu, 09 November 2024 - 05:00:00 Wib Globenewswire
Yossi Carmil to Step Down as CEO After Nearly 20 Years
Rabu, 06 November 2024 - 20:30:00 Wib Globenewswire
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as Well as
Sabtu, 02 November 2024 - 03:58:04 Wib Globenewswire
Teva Statement on European Commission Decision; Company to Appeal
Kamis, 31 Oktober 2024 - 18:30:00 Wib Globenewswire
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Selasa, 08 Oktober 2024 - 18:30:00 Wib Globenewswire
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
Kamis, 03 Oktober 2024 - 20:00:00 Wib Globenewswire
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
Selasa, 01 Oktober 2024 - 18:31:45 WibTerpopuler
Index
1
Dandim Dumai Laksanakan Pengawasan Program Dapur Makan Bergizi
Dibaca: 125 Kali
2
3
4
Terkini
Index
-
-
-
-
Dandim Dumai Laksanakan Pengawasan Program Dapur Makan Bergizi
10 Januari 2026